Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has entered into a binding term sheet to acquire substantially all assets and liabilities of Molecule, a Canadian AI company, for a total purchase price of $10 million, payable in cash and shares [2][3][4] Company Overview - Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company focused on enhancing cancer therapy outcomes by developing novel drugs that sensitize cancer cells to radiation therapy [4] - The company's mission is to advance precision medicine approaches to radiotherapy, improving treatment efficacy and patient quality of life [4] Acquisition Details - The acquisition will involve a total purchase price of $10 million, with the payment structure consisting of cash and Shuttle common stock, determined at Shuttle's discretion and contingent on performance milestones [2][3] - The transaction is subject to satisfactory completion of mutual due diligence and execution of final transaction documents [3] Strategic Importance - The acquisition is viewed as a strategic step to expand Shuttle's technological capabilities, particularly through Molecule's AI platform, which offers advanced tools for molecular modeling and predictive analytics [4]